Author Archives: admin

ONCpulse™ launched: rapid on-demand custom insights

We are thrilled to announce the launch of our newest subscription service: ONCpulse™. Realizing that many of our clients struggle with obtaining rapid insights to improve their decision-making, MDoutlook has developed ONCpulse.

ONCpulse delivers rapid, on-demand insights from verified, high quality cancer treaters and experts: ONCpulse
Rapid: Delivering actionable insights within 72 hours
Right: Engaging verified, high-quality cancer treaters and experts
Reach: Covers all cancers and geographies, accessing more than 100,000 cancer treaters globally
Relevant: Answers your specific questions through customized questions

Clients pre-purchase a set research bank of insights that they can implement on-demand. This drives transparency, eases client operations, creates flexibility in timing and scope, and most importantly delivers clients the desired, actionable insights within 72 hours. ONCpulse utilized proprietary assets including the MDoutlook network and technology.

For more information, view the ONCpulse page here, and contact the ONCpulse team at [email protected] or +1.404.496.4136.

Good Question – PM360 Guest Commentary

Our President and Founder, Jan Heybroek, was invited by PM360 to comment on recent concerns about the quality of (oncology) market research. The need to quickly track new product performance in priority markets is a key driver for this anxiety. This is relevant since standard prescription data, multi-disciplinary patient management, and varied institutional settings provide a scattered picture of the oncology market.

The industry can take major steps to ensure receipt of impeccable oncology market intelligence on a consistent basis. Jan provides 6 key measures to consider. Read his full column in PM360.

For more information on how MDoutlook provides impeccable and actionable disease intelligence, navigate our site and contact us here.

 

Rapid and Actionable Insights on Clinical Impact of ESMO 2017

After every major conference, MDoutlook provides valuable insights to our clients on the impact of new data presented. With the 2017 ESMO conference here, we are planning a series of syndicated studies. Final disease focus will be updated following our analysts’ review of new data presented.

As an example of syndicated research coming out of this year’s ASCO, please click on the images below for an overview of typical structure and contents of our Rapid Insights reports, and 2 insight slides.

If you would like to participate in the ESMO research or receive more details about our rapid conference insight reports, contact us by calling +1.404.496.4136 or dropping us a line here.

Contents of MDoutlook Rapid Insights Reports

MDoutlook_Rapid Insights Report Contents

Source of Abstract Awareness

MDoutlook_ASCO 2017 Abstract Source of Awareness

Physician Time on ASCO Exhibit Floor

MDoutlook_ASCO 2017 Exhibit Attendance

Case Study: Competitive Treatment Driver Analysis

At MDoutlook, we focus on providing actionable insights to our clients. These insights can provide valuable data to improve market share and compare and contrast our client’s products to those of their competition. Below is a case study outlining the main reasons taxanes are not considered for use following paclitaxel treatment in ovarian cancer.

Customer: Global pharmaceutical company expanding their disease portfolio into new therapeutic areas.

Challenge: Client needed to compare and contrast treatment decision drivers between competitive therapies as input for their clinical development and commercialization planning.

Unique MDoutlook proposition: 

  • Develop comprehensive questionnaire to address both quantitative treatment market share analysis while differentiating qualitative decision driver attributes often retrieved by different research methodologies (e.g. qualitative)
  • Panel Composition: 100 screened ovarian cancer treaters
  • Comparative Analysis:
    • By competitive therapies
    • Academic vs. community practice

Value delivered: 

  • Actionable insights to guide patient segmentation, commercial positioning and messaging
  • Robust and projectable quantitative market share analysis
  • Sophisticated qualitative insights generated by a quantitative study methodology that increased the study efficiencies and shortened the study timeline

Send an email to [email protected] to learn more.

july email image

Rapid Insights on Clinical Impact of ASCO

Whether it is the impact of the future usage in ALK positive lung cancer in first line of alectinib over the current standard of care or the potential use of DNA Disease repair in advanced BRCA-related breast cancer, many innovations in cancer treatment will be having an impact on the treatment protocols moving forward.

After every major conference, MDoutlook provides valuable insights to our clients on the impact of new data presented. With the 17 ASCO conference behind us, we will be generating syndicated reports in the following therapy areas:

• Bladder
• Breast
• Hematology: AML, CML
• Hepato-Cellular Carcinoma
• Melanoma
• Non-small cell lung cancer
• Prostate
• Renal Cell Carcinoma

If you would like to purchase or receive more details about our post conference syndicated reports, contact us by calling +1.404.496.4136 or dropping us a line here.

Post ASCO Results

Whether it is the impact of the future usage in ALK positive lung cancer in first line of alectinib over the current standard of care or the potential use of DNA Disease repair in advanced BRCA-related breast cancer, many innovations in cancer treatment will be having an impact on the treatment protocols moving forward.

After every major conference, MDoutlook provides valuable insights to our clients on the impact of new data presented. With the 17 ASCO conference behind us, we will be generating syndicated reports in the following therapy areas:

• Bladder
• Breast
• Hematology: AML, CML
• Hepato-Cellular Carcinoma
• Melanoma
• Non-small cell lung cancer
• Prostate
• Renal Cell Carcinoma

If you would like to purchase or receive more details about our post conference syndicated reports, email me at [email protected]

Researching the Impact of Chicago

Did you know that attendees at ASH in 2016 had B-cell Lymphoma1.7x as many patients with B-cell lymphomas as physicians who did not attend? Would you also be surprised to know that their distribution as to the types of B-cell lymphomas seen are remarkably consistent?

Now think about how that knowledge will drive different insights when measuring the impact of your clinical data announcements at conferences.

After every major conference, MDoutlook provides valuable insights to our clients on the impact of new data presented. This year, immediately following the ASCO meeting, we will be producing syndicated reports in the following therapy areas:

• Bladder
• Breast
• Hematology: AML, CML
• Hepato-Cellular Carcinoma
• Melanoma
• Non-small cell lung cancer
• Prostate
• Renal Cell Carcinoma

If you would like to purchase or receive more details about our post conference syndicated reports, email me at [email protected].

There are still a few spots open to include your proprietary questions if you commit before ASCO.

Click Here to sample the full report from the 2016 ASH meeting on NHL B-cell Lymphoma.

CEO/CFO Interview with Jan Heybroek, President MDoutlook

Earlier this month our President and Founder Jan Heybroek was interviewed by Lynn Fosse, Senior Editor of CEO/CFO Magazine. The interview discusses the concept and vision behind MDoutlook, how MDoutlook delivers value to its clients and the on-going engagement with oncologists and ThoughtLeaders.

“We have developed a platform and a network of more than one hundred thousand cancer physicians that we have identified, researched and validated as being responsible and active in the management of cancer…We invite these physicians, typically by survey emails, to participate in research. Physicians respond to us in a secure environment to the questions that we have developed with our client partners. We have MDs and PhDs on the staff who review these responses and pull together reports that we then share back with both sponsors and participants.”, Jan said.

You can read the full interview here: CEOCFO Magazine Interview with Jan Heybroek.

For more information about MDoutlook, contact us at [email protected] or +1.404.496.4136.

Preferred Interactions with ThoughtLeaders

april 25 landing page pictureWhile typically, you would assume that oncologists would prefer face to face interactions with ThoughtLeaders, our poll demonstrated different results.

When asked, “What is the preferred method of interacting with ThoughtLeaders?” over half of those polled responded via computer.

Remember this statistic the next time you consider flying a ThoughtLeader to a remote location to meet with cancer treaters.

To see how MDoutlook is able to provide you further actionable intelligence, email me at [email protected]

National Versus Regional ThoughtLeaders

Assumptions have been made for years that nationally recognized ThoughtLeaders are substantially more effective at modifying treatment behavior than regional or local experts, thus commanding a larger honorarium.

However, in MDoutlook’s new Insights & Influence Report on the U.S. market, one section analyzes the impact that national, regional, and local ThoughtLeaders, as well as peer groups, have on influencing oncologists’ treatment behavior. This report has been developed in partnership with Medallion Healthcare.

IIR Q11
The results show, while national U.S. ThoughtLeaders do have more overall influence, the gap between the national experts and the regional experts is found to be much smaller than anticipated.

MDoutlook’s Insights & Influence Report is a comprehensive survey of oncologists which measures the impact of various intelligence strategies employed and how large of an impact those strategies have on influencing oncologists’ treatment behaviors. If you are interested in purchasing the full report, click here.

At MDoutlook, we can leverage our proprietary database of over 12,000 validated oncology ThoughtLeaders and panel of 110,000+ cancer treaters globally to assist you. Click here to learn more.